2 Months Ago
1 Min Read

INBX down -6%. A closer look at what's happening:

+7.59% 24h

Inhibrx, Inc. (INBX) is trading -6% lower at $22.99 today.

  • GAAP EPS: -$0.97, $0.19 below estimates
  • Revenue: $0.71M, misses by $0.36M
  • PT Lowered to $48 at Credit Suisse

Inhibrx, Inc. has been trading between a 52-week high of $47.9 and a 52-week low of $7.67. The stock has a market cap of $898 Million.

Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. Inhibrx has collaborations with bluebird bio, Bristol-Myers Squibb and Chiesi.


Inhibrx Inc. PT Lowered to $48 at Credit Suisse
Investing.com 08-09-22

Inhibrx GAAP EPS of -$0.97 misses by $0.19, revenue of $0.71M misses by $0.36M
Seeking Alpha 08-08-22

Inhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
PR Newswire 08-08-22

Daily Biotech/Pharma Pulse: July 20, Featuring Inhibrx (INBX) In View Of Institutional Buying (NASDAQ:INBX)
Seeking Alpha 07-20-22

HYZN, MAXN and MBUU among after hour movers
Seeking Alpha 07-05-22